News | Heart Failure | September 20, 2019

Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak

New gift amounts to $8 million of giving to Beaumont from Max and Debra Ernst

Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak

September 20, 2019 — The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to consolidating cardiac care, particularly for patients with heart failure, into a convenient and comprehensive area.

Through this $5 million gift, Orchard Lake residents Max and Debra Ernst increased their support to Beaumont heart and vascular care to a total of $8 million. In 2009, the couple also gave $3 million to open the Ernst Cardiovascular Center in Memory of Ellen Ernst.

The new center includes:

“Through their incredible support to Beaumont for more than a decade, Max and Debra have demonstrated a commitment and desire to help others in our community. It has been an honor to work with them on this project,” said Marc Sakwa, M.D., chief, cardiovascular surgery, Beaumont, Royal Oak.

The 14,000-square-foot Max and Debra Ernst Heart Center is adjacent to the East Tower entrance of the hospital near the Ernst Cardiovascular Center. The new $9 million center not only combines outpatient heart services into one dedicated space; particularly those with heart failure, but also helps patients better manage their condition and reduce emergency center visits and hospital readmissions. 

“Max and Debra’s generosity has helped us to create an amazing resource that will allow us to better serve our patients, especially those living with heart failure,” said Simon Dixon, M.D., chair, cardiovascular medicine, Beaumont, Royal Oak.

Board-certified cardiologists, advanced practice providers, trained cardiac nurses, social workers and dietitians will provide medication monitoring, heart failure management and progressive therapies to not only improve symptoms, but also enhance quality of life. These services will be delivered with compassionate and specialized patient and family-centered care, in a convenient and easily accessible location for patients requiring more support.

The first Ernst multidisciplinary center offers innovative, collaborative approaches for the treatment of complex heart and vascular conditions, in addition to preventative heart screenings. The success of the first Ernst center created the need for expansion. Since the center opened in 2010, specialists have cared for more than 30,000 patients. It has become one of the nation’s premier programs for structural heart and valve disease and cardiac surgery.  

For more information: www.beaumont.org

Related Content

Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...